Remote Monitoring of Diabetes in Pregnancy: a Feasibility Study (Tele-Mum)

January 24, 2014 updated by: Professor Vivien Coates, University of Ulster

Remote Monitoring of Diabetes in Pregnancy: a Feasibility Study for a Randomised Controlled Trial

When women with diabetes become pregnant it is particularly important to control blood sugar levels to prevent complications. Women are advised to test their blood glucose levels seven times a day and to attend antenatal and diabetes clinics every 1-2 weeks throughout the pregnancy. For those living in rural areas in the North and West of Ireland getting to a hospital specialising in the management of diabetes and pregnancy on such a regular basis can be a challenge.

Telemonitoring provides a possible solution to this problem by allowing patients to monitor their vital signs at home and transmit the information via telephone to their healthcare provider. If women could be safely monitored remotely for every other appointment it would mean that they would only need to visit the hospital once a month on a routine basis but with the option of attending the hospital if the remote telemonitoring indicated that this were necessary.

The aim of this study is to assess the feasibility and the acceptability of using remote telemonitoring facilities between antenatal women with gestational diabetes and the diabetes team and the possibility of replacing alternate diabetic review clinics with remote telemonitoring. In addition this study will explore the feasibility of running a full randomised control trial of this topic.

Women will be asked to monitor their blood sugar levels seven times a day which is part of usual care. However those in the remote telemonitoring group will be asked to measure their blood sugar using a meter that can transmit the results via a telephone line and to transmit them weekly. They will also be asked to measure their blood pressure and weight weekly and to download these results weekly for a health care professional to review. These results will be reviewed on a weekly basis by a health care professional who will contact the patient if necessary to discuss the results. Women will be followed-up from the date of diagnosis through to delivery.

Both staff and patients will be asked to give their views on the safety and acceptability of remote telemonitoring through questionnaires, focus groups or interviews. The management decisions made on reviewing the intervention group in clinic and reviewing remote telemonitoring results will also be recorded. In order for remote telemonitoring to be a viable replacement for clinic review it must allow health care professionals to make comparable management decisions. Clinical data will be collected in order to provide descriptive statistics for those who take part and to ensure that this information could be collected in any future Randomised Control Trial (RCT) looking at this topic.

Study Overview

Status

Completed

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Donegal
      • Letterkenny, Donegal, Ireland
        • Letterkenny General Hospital
      • Londonderry, United Kingdom, BT47 6SB
        • Altnagelvin Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Pregnant
  • Gestational Diabetes or IGT following an oral glucose tolerance test performed at the 24-28 week screening appointment
  • Able to use the telehealth equipment following training by staff from the company providing telehealth services
  • Have sufficient communication skills [hearing, speech & language] to be fully involved.
  • Willing to use one of the approved blood glucose meters for self monitoring of blood glucose, for the duration of the study.

Exclusion Criteria:

  • Previously diagnosed Type 1 diabetes or Type 2 diabetes as evidenced by medical records.
  • Other diagnosed medical problems or medical therapy such as steroid therapy that would influence blood glucose control and to be decided by the endocrinologist prior to recruitment. Such exclusions to be noted by the endocrinologist or diabetes nurse specialist.
  • Previous gestational diabetes is not an exclusion criterion.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: HEALTH_SERVICES_RESEARCH
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Telemonitoring
The telemonitoring group will receive usual care but be asked to download their blood sugar readings and take a blood pressure and weight measurement each week. This will be reviewed by their diabetes health care team to assess the possibility of replacing alternate anti-natal/diabetes clinics with telemonitoring review in a future study. Acceptability to staff and patients will be assessed through a questionnaire (patients only) and qualitative interviews.
Use of telemonitoring facilities to monitor weight, blood pressure and blood sugar during pregnancy complicated by gestational diabetes
ACTIVE_COMPARATOR: Control group
Control group will consist of usual care and review at clinic.
The control group will receive usual diabetes/antinatal care. The outcomes from usual care will be compared with the outcomes from the telemonitoring group in order to ensure that it provides comparable care.
Other Names:
  • Usual care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient satisfaction
Time Frame: At 36-39 weeks gestation

The previously validated 'Telemedicine satisfaction and usefulness questionnaire' will be used to assess patient satisfaction with the telemonitoring service.

Qualitative interviews exploring the patient experience of telemonitoring will also be carried out and then analysed using the framework approach. An adapted version of this questionnaire looking specifically at the use of a blood glucose meter will be given to the control group.

At 36-39 weeks gestation
Health care staff satisfaction
Time Frame: At completion of the study estimated to be January 2013
The professionals involved in caring for the women using remote telemonitoring technology in antenatal or diabetes clinics will be invited to take part in a focus group at each site. If it is not possible to arrange a time and place suitable for staff in order to hold a focus group it may be necessary to hold one to one structured interviews with staff. The questions used in the focus group will aim to assess the acceptability of telemonitoring to health care staff who use it.
At completion of the study estimated to be January 2013
Management decision comparison
Time Frame: At weekly clinic or telemonitoring review from time recruited into study to delivery, estimated at an average of twelve weeks.
Weighted kappa will be used to meaure the level of agreement in between clinic and telemonitoring review management decisions (in excess of the amount of agreement that we would expected by chance). This will allow the determination of inter-rater, intra-rater and inter-institutional agreement between clinic and telemonitoring review management decisions.
At weekly clinic or telemonitoring review from time recruited into study to delivery, estimated at an average of twelve weeks.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
HbA1c
Time Frame: Monthly for duration of participation in study, estimated at 2-3 months
HbA1c mmol/l and IFCC units
Monthly for duration of participation in study, estimated at 2-3 months
Mean fasting blood glucose
Time Frame: Weekly for duration of participation in study, estimated at 12 weeks
mmol/l plasma glucose
Weekly for duration of participation in study, estimated at 12 weeks
Blood pressure
Time Frame: Weekly for duration of participation in study, estimated at 12 weeks
mmHg
Weekly for duration of participation in study, estimated at 12 weeks
Gestational age at delivery
Time Frame: At delivery
Gestational age in weeks at delivery
At delivery
Type of delivery
Time Frame: At delivery
Vaginal or Caesarean section
At delivery
Pre-eclampsia
Time Frame: At delivery
Presence or absence of any pre-eclampsia
At delivery
Documented problems with pregnancy
Time Frame: At delivery
Presence of any documented problems during pregnancy
At delivery
Weight of baby
Time Frame: At birth
Weight in kg
At birth
Apgar score
Time Frame: At birth
Apgar score at one and five minutes (out of 10)
At birth
Admission to neonatal unit
Time Frame: At one day after birth
Whether the baby needed admission to the neonatal unit
At one day after birth
Respiratory distress
Time Frame: At one day after birth
Presence of any episodes of documented Respiratory distress in first 24 hours of life
At one day after birth
Jaundice
Time Frame: At one day after birth
Presence of any jaundice in first 24 hours of life
At one day after birth
Neonatal hypoglycaemia
Time Frame: At one day after birth
Presence of any documented episodes of neonatal hypoglycaemia in first 24 hours of life
At one day after birth
Shoulder dystocia
Time Frame: At birth
Presence of any shoulder dystocia
At birth
Malformations
Time Frame: At delivery
Any malformations at delivery
At delivery
Post-prandial blood glucose
Time Frame: Weekly for duration of participation in study, estimated at 12 weeks
mmol/l plasma glcuose
Weekly for duration of participation in study, estimated at 12 weeks
Length of baby
Time Frame: At birth
centimeters
At birth
Macrosomia
Time Frame: At birth
Presence or absence of macrosomia
At birth
Head circumference
Time Frame: At birth
centimeters
At birth
Average number of monitoring episodes per day
Time Frame: At delivery
Average number of monitoring episodes per day
At delivery
Number of downloads missed
Time Frame: At delivery
Number of downloads missed by those in the telemonitoring group
At delivery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Vivien E Coates, PhD, University of Ulster

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2012

Primary Completion (ACTUAL)

March 1, 2013

Study Completion (ACTUAL)

May 1, 2013

Study Registration Dates

First Submitted

June 22, 2012

First Submitted That Met QC Criteria

June 26, 2012

First Posted (ESTIMATE)

June 28, 2012

Study Record Updates

Last Update Posted (ESTIMATE)

January 28, 2014

Last Update Submitted That Met QC Criteria

January 24, 2014

Last Verified

January 1, 2014

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gestational Diabetes

Clinical Trials on Telemonitoring

Subscribe